Revive Therapeutics Ltd
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$12.56M
-0.03
Revive Therapeutics Ltd. engages in the research, development, and commercialization of drugs for disorders and infectious diseases. The company is headquartered in Toronto, Ontario. The company went IPO on 2013-07-12. The firm is focused on the research and development of therapeutics for infectious diseases and medical countermeasures. The company is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. The firm is also advancing the development of Psilocybin and molecular hydrogen therapeutics through various programs. The firm's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).
Revive Therapeutics Ltd. engages in the research, development, and commercialization of drugs for disorders and infectious diseases. The company is headquartered in Toronto, Ontario. The company went IPO on 2013-07-12. The firm is focused on the research and development of therapeutics for infectious diseases and medical countermeasures. The company is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. The firm is also advancing the development of Psilocybin and molecular hydrogen therapeutics through various programs. The firm's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).
Recently from Cashu
Couldn't load Cashu news
Something went wrong. Try refreshing the page.